The single-arm screening Phase 2 trial is being conducted at seven centres across Canada and will enroll up to 30 patients whose brain tumour is in first relapse during or following primary therapy.
The primary endpoint of the trial is a combination of objective response rate and early progression.
PX-866 is a small molecule compound designed to inhibit the activity of phosphatidylinositol-3-kinase (PI-3K), a component of an important cell survival signaling pathway.